IN2014DN01605A - - Google Patents

Info

Publication number
IN2014DN01605A
IN2014DN01605A IN1605DEN2014A IN2014DN01605A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A IN 1605DEN2014 A IN1605DEN2014 A IN 1605DEN2014A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A
Authority
IN
India
Prior art keywords
gene
ret
fusion
cases
mutation
Prior art date
Application number
Other languages
English (en)
Inventor
Takashi Kohno
Koji TSUTA
Original Assignee
Nat Cancer Ct
Lsip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct, Lsip Llc filed Critical Nat Cancer Ct
Publication of IN2014DN01605A publication Critical patent/IN2014DN01605A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
IN1605DEN2014 2011-08-04 2012-08-03 IN2014DN01605A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011171256 2011-08-04
PCT/JP2012/069799 WO2013018882A1 (ja) 2011-08-04 2012-08-03 Kif5b遺伝子とret遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法

Publications (1)

Publication Number Publication Date
IN2014DN01605A true IN2014DN01605A (zh) 2015-05-15

Family

ID=47629396

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1605DEN2014 IN2014DN01605A (zh) 2011-08-04 2012-08-03

Country Status (8)

Country Link
US (1) US9216172B2 (zh)
EP (1) EP2740742B1 (zh)
JP (1) JP6032616B2 (zh)
KR (1) KR20140047138A (zh)
CN (1) CN103764676A (zh)
CA (1) CA2848369A1 (zh)
IN (1) IN2014DN01605A (zh)
WO (1) WO2013018882A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
JP5780527B2 (ja) 2010-09-02 2015-09-16 学校法人 久留米大学 単分子dnaから形成される環状dnaの作成方法
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
JP6066209B2 (ja) 2011-08-31 2017-01-25 学校法人 久留米大学 Dna分子の環状化において単分子による環状化dnaのみを選別する方法
US10023855B2 (en) * 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
EP2902029B1 (en) 2012-09-25 2018-08-08 Chugai Seiyaku Kabushiki Kaisha Ret inhibitor
WO2015025866A1 (ja) 2013-08-20 2015-02-26 独立行政法人国立がん研究センター 肺がんで見出された新規融合遺伝子
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
SI3322706T1 (sl) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
CN105255927B (zh) * 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
US10030005B2 (en) 2015-11-02 2018-07-24 Blueprint Medicines Corporation Inhibitors of RET
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JP7105774B2 (ja) * 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20210290620A1 (en) 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
EP3674325A4 (en) * 2017-08-21 2021-11-03 Taiho Pharmaceutical Co., Ltd. HYBRID PROTEIN OF DCTN1 AND RET PROTEIN
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019195471A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての縮合複素環式化合物
CN111154872A (zh) * 2019-12-31 2020-05-15 浙江大学 用于检测肺癌驱动性基因突变的探针及试剂盒
CN111909987A (zh) * 2020-07-31 2020-11-10 浙江科途医学科技有限公司 用于kif5b-ret融合基因检测的试剂组合物、试剂盒及检测***
CN113637709B (zh) * 2021-08-14 2023-01-17 中国农业科学院兰州兽医研究所 Kif5b基因作为靶点在抑制***病毒复制中的应用
JP2023177142A (ja) * 2022-06-01 2023-12-13 国立研究開発法人国立がん研究センター Retキナーゼ阻害剤によるがん治療の有効性を判定する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598052B2 (en) * 2005-10-11 2009-10-06 The Regents Of The University Of Michigan Expression profile of thyroid cancer
US20090136502A1 (en) 2005-10-24 2009-05-28 Toshimitsu Arai Preventives/Remedies for Cancer
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
KR20090094815A (ko) 2006-11-09 2009-09-08 애보트 게엠베하 운트 콤파니 카게 티로신 키나아제 억제제의 경구 투여를 위한 약제 투여형
WO2010000012A1 (en) * 2008-07-03 2010-01-07 The University Of Sydney Method for preventing transport of a neurotropic virus
EP2599878A4 (en) * 2010-07-26 2014-02-12 Astellas Pharma Inc NEW METHOD FOR DETECTING FUSED BODIES RET
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物

Also Published As

Publication number Publication date
KR20140047138A (ko) 2014-04-21
JPWO2013018882A1 (ja) 2015-03-05
WO2013018882A1 (ja) 2013-02-07
US9216172B2 (en) 2015-12-22
CA2848369A1 (en) 2013-02-07
JP6032616B2 (ja) 2016-11-30
EP2740742B1 (en) 2018-03-14
CN103764676A (zh) 2014-04-30
EP2740742A4 (en) 2015-06-17
EP2740742A1 (en) 2014-06-11
US20140221404A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
IN2014DN01605A (zh)
PH12018500317A1 (en) Salts of an lsd1 inhibitor
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
EA201792663A1 (ru) Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
MX2022015737A (es) Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
GB201103062D0 (en) Method
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
EP4116293A3 (en) Rho kinase inhibitors
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
WO2016065349A3 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MD3362066T2 (ro) Terapie combinată pentru tratamentul tumorilor maligne
EA201792344A1 (ru) Ген мужской стерильности пшеницы wms и его промотор специфичной для пыльника экспрессии и их применение
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
IN2014DN06164A (zh)
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
BR112014024487A2 (pt) métodos para aumentar a eficácia da terapia baseada em cd37
MX371119B (es) Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
MY169029A (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
MX2014014097A (es) Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
EA201301336A1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
WO2015048793A3 (en) Nucleic acid biomarker and use thereof